UPDATED: Novo Nordisk swallows Dicerna and its RNAi pipeline in $3.3B buyout
Early this year researchers at Novo Nordisk were beaming as they announced the first drug identified in their RNAi alliance with Dicerna was headed into the clinic. And now they’re coming back for the whole thing.
This morning the Copenhagen-based pharma giant put out word that it is buying Dicerna $DRNA — an RNAi pioneer that has had its up and downs over the years — for $3.3 billion. Novo is paying $38.25 a share — an 80% premium.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 124,400+ biopharma pros reading Endpoints daily — and it's free.